| Literature DB >> 31331115 |
Musafiri Karama1, Beniamino T Cenci-Goga2,3, Mogaugedi Malahlela2, Anthony M Smith4, Karen H Keddy4, Saeed El-Ashram5,6, Lawan M Kabiru7, Alan Kalake8.
Abstract
Shiga toxin-producing Escherichia coli (STEC) isolates (N = 38) that were incriminated in human disease from 2006 to 2013 in South Africa were characterized by serotype, virulence-associated genes, antimicrobial resistance and pulsed-field gel electrophoresis (PFGE). The isolates belonged to 11 O:H serotypes. STEC O26:H11 (24%) was the most frequent serotype associated with human disease, followed by O111:H8 (16%), O157:H7 (13%) and O117:H7 (13%). The majority of isolates were positive for key virulence-associated genes including stx1 (84%), eaeA (61%), ehxA (68.4%) and espP (55%), but lacked stx2 (29%), katP (42%), etpD (16%), saa (16%) and subA (3%). stx2 positive isolates carried stx2c (26%) and/or stx2d (26%) subtypes. All pathogenicity island encoded virulence marker genes were detected in all (100%) isolates except nleA (47%), nleC (84%) and nleD (76%). Multidrug resistance was observed in 89% of isolates. PFGE revealed 34 profiles with eight distinct clusters that shared ≥80% intra-serotype similarity, regardless of the year of isolation. In conclusion, STEC isolates that were implicated in human disease between 2006 and 2013 in South Africa were mainly non-O157 strains which possessed virulence genes and markers commonly associated with STEC strains that have been incriminated in mild to severe human disease worldwide. Improved STEC monitoring and surveillance programs are needed in South Africa to control and prevent STEC disease in humans.Entities:
Keywords: PFGE; STEC; antimicrobial resistance; human; virulence
Year: 2019 PMID: 31331115 PMCID: PMC6669688 DOI: 10.3390/toxins11070424
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Proportions of essential chromosomal and plasmid-encoded virulence-associated genes in Shiga toxin-producing Escherichia coli (STEC) isolates from humans in South Africa.
| No | Year | Serotype |
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 2007 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2008 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2010 | O111:H8 | + | − | − | − | + | + | + | − | − | − | − |
|
| 2010 | O26:H11 | + | − | − | − | + | − | − | − | − | − | − |
|
| 2011 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2011 | O157:H7 | − | + | + | + | + | + | + | + | + | − | − |
|
| 2010 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2010 | O117:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2010 | O157:H7 | − | + | + | + | + | + | + | + | + | − | − |
|
| 2003 | ONT:H8 | + | − | − | − | + | − | − | − | − | − | − |
|
| 2006 | O111:H8 | + | − | − | − | + | + | − | − | − | − | − |
|
| 2006 | O117:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2006 | O117:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2007 | O22:H16 | − | + | − | − | − | − | − | − | − | − | − |
|
| 2007 | O8:H19 | + | + | + | + | − | + | − | + | − | + | − |
|
| 2007 | O107:H7 | + | + | − | + | − | + | − | + | − | + | − |
|
| 2007 | O107:H7 | + | + | − | + | − | + | − | + | − | + | − |
|
| 2007 | O107:H7 | + | + | − | + | − | + | − | + | − | + | − |
|
| 2007 | O113:H21 | − | + | + | + | − | + | − | + | − | + | + |
|
| 2009 | ONT:H21 | + | − | − | − | − | − | + | − | − | + | − |
|
| 2009 | O111:H8 | + | − | + | − | − | − | − | − | − | − | − |
|
| 2009 | O111:H8 | + | − | − | − | + | + | − | − | − | − | − |
|
| 2009 | O156:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2009 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2009 | O157:H7 | + | + | + | + | + | + | + | + | + | − | − |
|
| 2009 | O111:H8 | + | − | − | − | + | + | − | − | − | − | − |
|
| 2012 | O117:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2012 | O117:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2012 | O157:H7 | − | + | + | + | + | + | + | + | + | − | − |
|
| 2012 | O157:H7 | − | + | + | + | + | + | + | + | + | − | − |
|
| 2013 | O118:H16 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2013 | O156:H7 | + | − | − | − | − | − | − | − | − | − | − |
|
| 2009 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2013 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2008 | O111:H8 | + | − | − | − | + | + | − | − | − | − | − |
|
| 2008 | O26:H11 | + | − | − | − | + | + | + | + | − | − | − |
|
| 2010 | O5:HNT | + | − | + | − | + | + | − | + | − | − | − |
|
| 2008 | O5:HNT | + | − | + | − | + | + | − | + | + | − | − |
| TOTAL | 32 | 11 | 10 | 10 | 23 | 26 | 16 | 21 | 6 | 6 | 1 | ||
| % Positive | 84 | 29 | 26 | 26 | 61 | 68 | 42 | 55 | 16 | 16 | 3 |
Figure 1Distribution of virulence-associated genes in STEC isolates from humans in South Africa.
Figure 2Antimicrobial resistance profiles of STEC isolates from humans in South Africa.
Figure 3Dendrogram showing relationships among STEC isolates that were incriminated in human disease in South Africa from 2006 to 2013.